MedicarePartD.guide

A non-government resource built from CMS public data

ustekinumab biosimilars on Prescription Blue Select (S5584-001)

Wezlana, Selarsdi, Pyzchiva and others

Covered, with prior authorization required.

Tier 5 (specialty tier). Quantity limit of 1 per 28 days.

$1,871.97
Patient pays / month, after deductible
$2,333.22
Patient pays / month, before the $615.00 deductible
Not offered
Patient pays / 90 days by mail
$0
After the yearly $2,100.00 out-of-pocket cap

USTEKINUMAB 45 mg/.5mL Injection, Solution at a preferred retail pharmacy, from the plan's negotiated price of $7,487.86 for a month. Other covered strengths are listed below.

Prior authRequired on all 3 covered forms· The plan decides within 72 hours, or 24 if expedited· If denied, the prescriber can ask the plan to reconsider (an appeal)
All 3 covered strengths and forms
FormTierPatient pays / monthLimits
USTEKINUMAB 45 mg/.5mL Injection, Solution5$1,871.97PA · 1 per 28 days
USTEKINUMAB 45 mg/.5mL Injection, Solution5$2,244.91PA · 1 per 28 days
USTEKINUMAB 90 mg/mL Injection, Solution5$3,743.94PA · 2 per 28 days

Other IL-17 and IL-23 biologics on this plan

Verify with the plan before prescribing or filling. Member services: (800)565-1770. Data from the CMS 2026 Part D formulary and pricing files. Full plan details

Plan ID s5584-001